Dr. AJAY AURORA

Abstract

To evaluate safety & efficacy of Suprachoroidal Injection of centrifuged Triamcinolone Acetonide(cTA) with novel Suprachoroidal Injection Device (SCID) in patients with macular edema due to diverse uveal/retinal pathologies.

SCITA 0.1ml of cTA was given in 24 eyes of 22 patients with 30G needle using novel SCID. Three eyes had repeat second injection and three had a third repeat injection. The angulation of the base plate to the scleral entry was a critical determinant of correct plane of injection. BCVA, IOP and central subfield thickness (CST/SDOCT) was measured on day (D) 1-7, 30-60, 90-120 and140-160.

SCITA was mostly pain free, well tolerated and no eye developed retinal/Choroidal injury. Mean baseline CST decreased to normal range at day 7-30,was maintained from 80-158 days. No eye had increased IOP if there was no intravitreal injection of TA.Centrifugation increased TA action beyond 5 months and it may be used as an alternative to intravitreal injection of Ozurdex.